Ken Kulsa is an experienced financial professional currently serving as the Senior Manager of Financial Planning & Analysis for R&D and GMO at Haemonetics since February 2024. In this role, Ken acts as a business partner to the CTO and Chief Medical Officer, driving the monthly forecasting and reporting process, managing strategic plans, and leading Board of Directors presentation slides. Prior to Haemonetics, Ken worked as a Financial Consultant at Robert Half, supporting a Dublin-based software logistics company. Ken’s extensive experience at PTC includes roles as Senior Director and Director of Financial Planning and Analysis, managing budgets and forecasts for a large division. Earlier roles included Senior Financial Analyst at MultiPlan, where Ken conducted financial analysis and due diligence, and Project Accountant, implementing key financial processes. Ken holds an MBA and a Bachelor's degree in Accounting, both from Northeastern University.
This person is not in any teams
This person is not in any offices